Literature DB >> 29377152

A presynaptic congenital myasthenic syndrome attributed to a homozygous sequence variant in LAMA5.

Ricardo A Maselli1, Juan Arredondo1, Jessica Vázquez1, Jessica X Chong2, Michael J Bamshad2,3,4, Deborah A Nickerson3, Marian Lara1, Fiona Ng1, Victoria Lee Lo1, Peter Pytel5, Craig M McDonald6.   

Abstract

We report a severe defect of neuromuscular transmission in a consanguineous patient with a homozygous variant in the laminin α5 subunit gene (LAMA5). The variant c.8046C > T (p.Arg2659Trp) is rare and has a predicted deleterious effect. The affected individual, who also carries a rare homozygous sequence variant in LAMA1, had normal cognitive function, but magnetic resonance brain imaging showed mild volume loss and periventricular T2 prolongation. Repetitive nerve stimulation at 2 Hz showed 50% decrement of compound muscle action potential amplitudes but 250% facilitation immediately after exercise, similar to that seen in Lambert-Eaton myasthenic syndrome. Endplate studies demonstrated a profound reduction of the endplate potential quantal content but normal amplitudes of miniature endplate potentials. Electron microscopy showed endplates with increased postsynaptic folding that were denuded or only partially occupied by small nerve terminals. Expression studies revealed that p.Arg2659Trp caused decreased binding of laminin α5 to SV2A and impaired laminin-521 cell adhesion and cell projection support in primary neuronal cultures. In summary, this report describing severe neuromuscular transmission failure in a patient with a LAMA5 mutation expands the list of phenotypes associated with defects in genes encoding α-laminins.
© 2018 New York Academy of Sciences.

Entities:  

Keywords:  LAMA5; congenital myasthenic syndrome (CMS); laminin α5; presynaptic

Mesh:

Substances:

Year:  2018        PMID: 29377152      PMCID: PMC6252105          DOI: 10.1111/nyas.13585

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  29 in total

1.  Interaction of agrin with laminin requires a coiled-coil conformation of the agrin-binding site within the laminin gamma1 chain.

Authors:  R A Kammerer; T Schulthess; R Landwehr; B Schumacher; A Lustig; P D Yurchenco; M A Ruegg; J Engel; A J Denzer
Journal:  EMBO J       Date:  1999-12-01       Impact factor: 11.598

Review 2.  The basement membrane/basal lamina of skeletal muscle.

Authors:  Joshua R Sanes
Journal:  J Biol Chem       Date:  2003-01-29       Impact factor: 5.157

Review 3.  Structure and function of laminin: anatomy of a multidomain glycoprotein.

Authors:  K Beck; I Hunter; J Engel
Journal:  FASEB J       Date:  1990-02-01       Impact factor: 5.191

4.  A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release.

Authors:  A G Engel; E H Lambert; M R Gomez
Journal:  Ann Neurol       Date:  1977-04       Impact factor: 10.422

5.  Aberrant differentiation of neuromuscular junctions in mice lacking s-laminin/laminin beta 2.

Authors:  P G Noakes; M Gautam; J Mudd; J R Sanes; J P Merlie
Journal:  Nature       Date:  1995-03-16       Impact factor: 49.962

6.  Structural and functional conservation of synaptotagmin (p65) in Drosophila and humans.

Authors:  M S Perin; P A Johnston; T Ozcelik; R Jahn; U Francke; T C Südhof
Journal:  J Biol Chem       Date:  1991-01-05       Impact factor: 5.157

7.  Mutations in LAMA1 cause cerebellar dysplasia and cysts with and without retinal dystrophy.

Authors:  Kimberly A Aldinger; Stephen J Mosca; Martine Tétreault; Jennifer C Dempsey; Gisele E Ishak; Taila Hartley; Ian G Phelps; Ryan E Lamont; Diana R O'Day; Donald Basel; Karen W Gripp; Laura Baker; Mark J Stephan; Francois P Bernier; Kym M Boycott; Jacek Majewski; Jillian S Parboosingh; A Micheil Innes; Dan Doherty
Journal:  Am J Hum Genet       Date:  2014-08-07       Impact factor: 11.025

8.  Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy.

Authors:  Sophie Nicole; Amina Chaouch; Torberg Torbergsen; Stéphanie Bauché; Elodie de Bruyckere; Marie-Joséphine Fontenille; Morten A Horn; Marijke van Ghelue; Sissel Løseth; Yasmin Issop; Daniel Cox; Juliane S Müller; Teresinha Evangelista; Erik Stålberg; Christine Ioos; Annie Barois; Guy Brochier; Damien Sternberg; Emmanuel Fournier; Daniel Hantaï; Angela Abicht; Marina Dusl; Steven H Laval; Helen Griffin; Bruno Eymard; Hanns Lochmüller
Journal:  Brain       Date:  2014-06-20       Impact factor: 13.501

9.  Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice.

Authors:  B L Patton; J H Miner; A Y Chiu; J R Sanes
Journal:  J Cell Biol       Date:  1997-12-15       Impact factor: 10.539

10.  Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII α1 Chain.

Authors:  Clare V Logan; Judith Cossins; Pedro M Rodríguez Cruz; David A Parry; Susan Maxwell; Pilar Martínez-Martínez; Joey Riepsaame; Zakia A Abdelhamed; Alice V R Lake; Maria Moran; Stephanie Robb; Gabriel Chow; Caroline Sewry; Philip M Hopkins; Eamonn Sheridan; Sandeep Jayawant; Jacqueline Palace; Colin A Johnson; David Beeson
Journal:  Am J Hum Genet       Date:  2015-11-25       Impact factor: 11.025

View more
  3 in total

1.  Pathogenic LAMA5 Variants and Kidney Disease.

Authors:  Judy Savige; Philip Harraka
Journal:  Kidney360       Date:  2021-12-30

2.  Recessive LAMA5 Variants Associated With Partial Epilepsy and Spasms in Infancy.

Authors:  Sheng Luo; Zhi-Gang Liu; Juan Wang; Jun-Xia Luo; Xing-Guang Ye; Xin Li; Qiong-Xiang Zhai; Xiao-Rong Liu; Jie Wang; Liang-Di Gao; Fu-Li Liu; Zi-Long Ye; Huan Li; Zai-Fen Gao; Qing-Hui Guo; Bing-Mei Li; Yong-Hong Yi; Wei-Ping Liao
Journal:  Front Mol Neurosci       Date:  2022-05-19       Impact factor: 6.261

Review 3.  The congenital myasthenic syndromes: expanding genetic and phenotypic spectrums and refining treatment strategies.

Authors:  An E Vanhaesebrouck; David Beeson
Journal:  Curr Opin Neurol       Date:  2019-10       Impact factor: 5.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.